Agenus Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:01AM CDT
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the first quarter ended March 31, 2014.
Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), GW Pharmaceuticals plc (NASDAQ: GWPH), Techne Corp. (NASDAQ: TECH) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1869-100free.
Technical Review on Top Gainers -- Research on Agenus, Alliance Fiber Optic Products, Susser Holdings, and Magellan Petroleum
PR Newswire - Tue Apr 29, 11:51AM CDT
The US stock markets saw a mixed sentiment on Monday, April 28, 2014, with the NASDAQ Composite closing at 4,074.40, down 0.03 %, the Dow Jones Industrial Average ending the session 0.53% higher at 16,448.74, and the S&P 500 gaining 0.32 % to finish the trading session at 1,869.43. The session saw a positive impact from Telecommunication Services, Consumer Staples, and Information Technology sectors along with a drag from Financials, Materials, and Consumer Discretionary sectors. A number of stocks saw large movements, including Agenus Inc. (NASDAQ: AGEN), Alliance Fiber Optic Products Inc. (NASDAQ: AFOP), Susser Holdings Corp. (NYSE: SUSS) and Magellan Petroleum Corp. (NASDAQ: MPET). Free technical research on AGEN, AFOP, SUSS and MPET can be downloaded upon signing up at:
Agenus to Report First Quarter 2014 Financial Results on May 8, 2014; Conference Call to Follow
Business Wire - Tue Apr 29, 10:30AM CDT
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2014 financial results before the market opens on May 8, 2014.
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
Hot Stock: Antigenics, Shares Gain 11.7% (AGEN)
Comtex SmarTrend(R) - Mon Apr 28, 10:40AM CDT
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 11.7% to $2.86 on 1.2x average daily volume. Antigenics has traded 1.0 million shares thus far today, vs. average volume of 866,000 shares per day. The stock has outperformed the Dow (11.7% to the Dow's 0.4%) and outperformed the S&P 500 (11.7% to the S&P's 0.1%) during today's trading.
Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies
Business Wire - Mon Apr 28, 6:01AM CDT
Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display(R) platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Agenus to Host Annual Meeting of Stockholders
Business Wire - Wed Apr 16, 10:45AM CDT
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
Positive Results on Intercept Pharma's OCA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:30PM CDT
Intercept Pharma announced positive additional data from the phase III study on obeticholic acid.
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
Glaxo Stops MAGE-A3 Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:14PM CDT
Glaxo announced that it has decided to terminate the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic.
Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 02, 8:22AM CDT
Let's take a look a four stocks -- MannKind , GlaxoSmithKline , Myriad Genetics , and Alnylam Pharmaceuticals -- all of which could loom large in health care headlines this Wednesday morning. FDA advisory panel recommends the approval of...
Update on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer
Business Wire - Wed Apr 02, 1:01AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains Agenus'QS-21 Stimulon(R) adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.
Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 5:47AM CDT
Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy?
The Week's Worst Clinical Failures
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
While there were plenty of winners last week, two losers stand out. The first failure belongs to GlaxoSmithKline . This giant is leading the industry with 20 new molecular entity approvals over the past six years. But its recent failure shows how...
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Agenus to Present at the 4th Annual Cancer Immunotherapy Conference
Business Wire - Wed Mar 26, 6:00AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus' checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. On March 27, 2014, a presentation on Checkpoint Modulators is scheduled for 8:30 am Eastern Time and a corporate presentation is scheduled for 2:15 pm Eastern Time.